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DMSO has a widespread use as a vehicle for water-insoluble therapeutic drug candidates but may also
exert disease-relevant pharmacological effects by itself. However, its inﬂuence on the CNS has hardly
been addressed. Here we examined the brain structure and function following chronic exposure to low
DMSO dose at a paradigm with ﬂawed synaptic connectivity in a preclinical transgenic mouse model for
Alzheimer's disease (APPSDL mice). DMSO treatment increased spine density in a region-speciﬁc manner
in the hippocampus of APPSDL mice ex vivo and in vivo. Moreover, DMSO exhibited clear inﬂuence on the
behavior of this mouse line by enhancing hippocampal-dependent spatial memory accuracy, modulating
hippocampal-independent olfactory habituation and displaying anxiolytic effect. Despite that most of the
action of DMSO was observed in animals with elevated Ab levels, the drug did not exert its function via
decreasing the oligomeric Ab species. However, challenging organotypic hippocampal slice cultures with
NMDA receptor antagonist MK-801 recapitulated the effect of DMSO on spine density, indicating a tuning
inﬂuence of DMSO on receptor signalization. Our ﬁndings demonstrate that DMSO should be considered
as a true bioactive compound, which has the potential to be a beneﬁcial adjuvant to counteract Ab-
mediated synaptotoxicity and behavioral impairment.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dimethyl sulfoxide (DMSO) is widely used in preclinical and
clinical research, as it enhances the entrance of water-insoluble
drug candidates into the central nervous system (Broadwell et al.,
1982). An ideal vehicle is expected to be biocompatible, reliable,
and devoid of biological actions per se. However, within the last
decades, pharmacological effects of DMSO have been reported, and
some of its biological activities have shown to be beneﬁcial against
various pathologies (Santos et al., 2003; Yu and Quinn, 1994).
As for many pharmaceutical compounds, the mechanism of
action of DMSO appears to be dependent of both the treatment
duration and the dose employed. While a consensus exists that
DMSO doses of 10% or higher are toxic in vivo (Hanslick et al., 2009),
the effects of low DMSO doses both in vitro (Hanslick et al., 2009;gy, University of Osnabrück,
e (L. Bakota).
Ltd. This is an open access article uKahler, 2000) and in vivo are still controversially judged (Galvao
et al., 2014). Intriguingly, particularly low DMSO concentrations
appear to profoundly inﬂuence neural network activities (Nakahiro
et al., 1992; Nasrallah et al., 2008; Obregon et al., 2005; Tamagnini
et al., 2014; Tsvyetlynska et al., 2005). Moreover, chronic DMSO
treatment has been shown to attenuate spatial memory deﬁcits
induced by ischemia (Farkas et al., 2004) suggesting that prolonged
DMSO administration has protective actions for the central nervous
system (CNS) under pathological conditions.
Memory deﬁcits have also been associated with abnormal Ab
levels in humans as well as in transgenic mice mimicking
amyloidosis-related disorders (Brouillette et al., 2012; Lesne et al.,
2006; Shankar et al., 2008). Synaptic failure is considered to be
the immediate cause of cognitive decline and memory dysfunction
in Alzheimer's disease (AD) (Dorostkar et al., 2015). Dendritic
spines are anatomical substrates for memory storage (Tackenberg
et al., 2009) and spine loss represents an early feature of AD
(Penazzi et al., 2016; Selkoe, 2002), occurring long before the
pathological plaque deposition of Ab. Previous studies showed thatnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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deﬁcits (Lacor et al., 2007; Shankar et al., 2007) and a drug acting as
NMDAR antagonist is currently used to attenuate clinical symptoms
during mild cognitive impairment (MCI) (Emre et al., 2010).
Elevated Ab levels further correlate with anxiety-like behavior (Lee
et al., 2004; Porter et al., 2003) or atypical olfactory-behavior
(Alvarado-Martinez et al., 2013; Cheng et al., 2013; Wesson et al.,
2010). These pathological phenotypes represent also relevant
criteria for the early diagnosis of neuropathology, such as AD or
Parkinson's disease (PD) (Baba et al., 2012; Berendse and Ponsen,
2006; Jimbo et al., 2011).
To date, only anxiolytic effects of DMSO have been reported
(Matheus et al., 1997) but effects on memory have not been
studied. Therefore the present study was designed to determine
the potential effect of chronic, low, non-toxic DMSO dose on
hippocampal plasticity and hippocampal-dependent behavior,
and whether this treatment may be beneﬁcial to rescue Ab-
mediated presymptomatic CNS alterations. We ﬁrst aimed to
analyze the consequence of DMSO (0.01%) treatment on spine
density using ex vivo hippocampal slice cultures prepared from
APPSDL mice and non-transgenic controls. APPSDL mice are a
model for the long prodromal phase of AD, since they develop Ab
plaques only after 18 months of age (Blanchard et al., 2003).
Furthermore, using this model, we also determined whether
spine modulation by DMSO involves NMDARs. Secondly, we hy-
pothesized that the genotype- and region-speciﬁc changes
observed ex vivo may also occur in the hippocampus of old male
transgenic and non-transgenic mice after a prolonged treatment
with a low DMSO (1%) dose. At last, we assessed whether such
plastic changes may inﬂuence hippocampus-dependent and -in-
dependent behavior, as well as basal home cage and spatial
memory-induced neuronal activities.2. Material and methods
2.1. Animals
General health assessment and behavioral testing were carried
out onmale transgenic APPSDL mice and their wild-type littermates.
Mice were 17e18 months old at the start of the testing. In addition,
adult 7e8 months old male mice from both genotypes were
incorporated into the behavioral assessment to evaluate the
behavioral performances of the old mice. For dendritic spine
analysis, double heterozygous transgenic EGFP/APPSDL mice were
generated by crossing transgenic homozygous EGFP mice (GFP M
line) (Feng et al., 2000) with heterozygous APPSDL mice. Mice were
individually housed per cage in a sterile room with 12/12-h light-
dark cycle. The room was maintained under constant tempera-
ture and humidity conditions. Water and food were available ad
libitum.
All animal studies were conducted in accordance to National
Institutes of Health guidelines and German animal care regulations
and approved by the ethical committee on animal care and use of
Lower Saxony, Germany.2.2. Drug treatment
Dimethyl sulfoxide (Merck KGaA, Darmstadt, Germany) was
provided to mice ad libitum at 1% (v/v), mixed in water. The drug
treatment was administrated during 14 days prior behavioral
testing and was maintained all along the behavioral procedures,
thus ending after 20 days of treatment.2.3. Organotypic hippocampal slice cultures and Sindbis virus
infection
Organotypic hippocampal slice cultures were generated from
postnatal days 7 (P7) mouse pups (Fig. 1B) that were cultured,
infected with Sindbis virus expressing EGFP, and ﬁxed as previously
described (Bakota et al., 2012; Sundermann et al., 2012). For treated
conditions, 0.01% DMSO, 50 mM MK-801 or both (Sigma Aldrich,
Munich, Germany) were applied in low-serum Nb-N1 medium. For
high-resolution imaging, pyramidal neurons located in the hippo-
campal regions CA1 and CA3 were selected.2.4. Spine analysis in the mouse brain
After 14 days of treatment mice were transcardially ﬁxed with
4% paraformaldehyde in PBS (w/v). The brains were removed, post-
ﬁxed overnight at 4 C and then transferred to PBS. Hundred mm
thick coronal sections were sliced on an automated vibratome
(Leica VT1200S, Leica Biosystems), ﬂoating sections were collected,
mounted with a Confocal-matrix (Micro-Tech-Lab, Graz, Austria)
and coverslipped. For imaging, neurons were randomly selected
from the dorsal hippocampus (approximately 1.58 mm from
Bregma) for each hippocampal subﬁeld: proximal CA3 (e.g. close to
the DG), CA2 and intermediate part of CA1 (Supplemental Fig. S2).
Borders of the CA regions were deﬁned with the help of the
nomenclature by Franklin and Paxinos (Franklin and Paxinos, 2007)
and Kohara and collaborators (Kohara et al., 2014).2.5. Spine imaging and quantiﬁcation
For both ﬁxed organotypic and mouse brain slices, image
acquisition and quantiﬁcation of EGFP expressing dendritic seg-
ments were performed as described earlier (Sundermann et al.,
2012; Tackenberg and Brandt, 2009).2.6. Design and behavioral procedures
To minimize the number of mice used in the experiments, the
same set of adult and oldmalemice from both genotypeswere used
for all behavioral testing. The testing began with an elevated-plus
maze test on day 14, followed by the olfactory behavior test on
day 15 and the Barnes maze test that started on day 17 of the DMSO
treatment period. Except for mice that did not participate in the
behavioral tasks (i.e., home cage condition), mice were daily
handled during 14 days, prior to the start of the behavioral pro-
cedures, to habituate them to the experimenter blinded to the
treatment condition and the genotype of mice.
See Supplementary information for the behavioral procedures
in detail.2.7. Immunohistochemistry
c-fos immunohistochemistry was performed on coronal brain
sections of 50 mm thickness from 17 to 18months old wild-type and
APPSDL mice that performed the Barnes maze task and from addi-
tional mice of both genotypes that did not participate in the task
(i.e., home cage, basal condition).
Mouse brain sections were produced from brain tissue blocks
neuroanatomically deﬁned as follows: the anterior part of the
dorsal hippocampus is between 1.58 mm and 1.74 mm from
Bregma; the lateral parietal cortex (LPar) and the retrosplenial
granular cortex (RSGc) between 1.46 mm and 2.06 mm.
Fig. 1. Chronic DMSO treatment modulates spine density in a genotype-speciﬁc manner in organotypic hippocampal slice cultures. (A) PC12 cell viability assay using MTT
reduction method with increasing DMSO concentrations. One way ANOVA showed signiﬁcantly decreased cell viability after 4 days treatment with 1% DMSO compared to untreated
culture. N ¼ 4 independent experiments run in triplicates. (B) Time line of the experimental design. Organotypic hippocampal slices were treated with 0.01% DMSO, 50 mMMK-801
or both during 4 days. (C) Representative high-magniﬁcation micrographs of dendritic segments from CA1 neurons, imaged in both untreated and DMSO treated slices of wild-type
and APPSDL mice. Scale bar, 5 mm. (D) Decreased spine density on dendritic segments from untreated APPSDL slices was signiﬁcantly attenuated by DMSO in a region-speciﬁc manner,
whereas the treatment reduced spine density on dendrites fromwild-type mice in both hippocampal regions; CA1 and CA3 regions, n ¼ 5 mice/group. (E) Blockage of NMDAR with
the antagonist MK-801 alone or MK- 801/DMSO decreased spine density from apical dendritic segments imaged from wild-type neurons located in the CA1 and CA3 regions but
speciﬁcally increased spine density on dendritic segments from APPSDL neurons located in CA1 region. N ¼ 3e6 mice/group. Numbers in bars represent the number of dendritic
segments analyzed in each experimental condition. All values are represented as mean ± S.E.M. *P < 0.05 and ***P < 0.001, (D and E) wild-type versus APPSDL, same experimental
condition. #P < 0.05, ##P < 0.01 and ###P < 0.001, signiﬁcantly decreased compared to untreated, same genotype. þ P < 0.05 and þþþ P < 0.001, signiﬁcantly increased compared
to untreated, same genotype. Factorial ANOVA, post-hoc Fisher's LSD for multiple comparisons. For detailed statistics see Supplementary Tables 1 and 2.
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Quantiﬁcation of the c-fos positive cell density was performed
on every third coronal section using the Machine Learning Based
Image Segmentation (MLBIS) method (Penazzi et al., 2014). See
Supplemental information and Supplemental Fig. S3 for details.2.9. Other methods and complementary information
For a detailed description of themethods regarding animal lines,
general health assessment, oligomeric Ab amount determination,MTT assay, immunohistochemistry and quantiﬁcation, see Sup-
plementary information.2.10. Statistical analysis
Statistical analysis was conducted using Statistica software
(StatSoft Inc, Tulsa, OK, USA). One-way, factorial and repeated-
measures ANOVA as well as Student's t-test were used in this
study, followed by either post-hoc Fisher's LSD for multiple com-
parisons, Tukey's test or Newman-Keuls. Detailed information of
the test applied is described in Supplementary information. All
Fig. 2. Chronic DMSO treatment modulates spine density in a genotype- and
region-speciﬁc manner in vivo. (A) Time line of the experimental design. EGFP and
EGFP/APPSDL male mice (17e18 months) received ad libitum either water (untreated)
or 1% DMSO in drinking water during 14 days. (B) Representative high-magniﬁcation
micrographs of dendritic segments from CA3 neurons imaged from untreated and
DMSO treated wild-type and APPSDL mice. Scale bar, 5 mm (C) DMSO treatment
signiﬁcantly increased spine density on neurons from APPSDL mice in CA2 region and
on CA3 neurons compared to their untreated counterpart, n ¼ 5 mice/group. No sig-
niﬁcant change occurred on APPSDL neurons from CA1 region that displayed reduced
spine density compared to wild-type mice under untreated condition. Numbers in bars
represent the number of dendritic segments analyzed in each experimental condition.
All values are represented as mean ± S.E.M. *P < 0.05, **P < 0.01 and ***P < 0.001, wild-
type versus APPSDL, same experimental condition. þ P < 0.05, signiﬁcantly increased
compared to untreated, same genotype. Factorial ANOVA followed by post-hoc Fisher's
LSD for multiple comparisons. For detailed statistics see Supplementary Table 3.
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set at P < 0.05.
3. Results
3.1. DMSO modulates dendritic spine density in a genotype-speciﬁc
manner in ex vivo hippocampal organotypic cultures
We ﬁrst determined a potential toxic effect of DMSO treatment
using a MTT reduction assay, an indicator of cell viability. As a
neural model, PC12 cells were exposed to 0.01%, 0.1% or 1% of DMSO
during 4 days (Fig. 1A). MTT conversion was signiﬁcantly altered at
1% DMSO but not at 0.1% or 0.01% (Fig. 1A, Supplementary Table 1).
To explore the effect of non-toxic dose of DMSO on dendritic spine
density, 0.01% DMSO was applied for 4 days to organotypic hip-
pocampal slice cultures fromwild-type and APPSDL mice (Fig.1B). In
the absence of DMSO, spine density was signiﬁcantly reduced on
dendritic segments from neurons of APPSDL mice in both CA1 and
CA3 regions (Fig. 1C and D, left, Supplementary Table 2), in agree-
ment with previous results (Tackenberg and Brandt, 2009). DMSO
treatment increased spine density in the CA1 region of APPSDL mice
and decreased spine density in both hippocampal regions of wild-
type mice (Fig. 1C and D, right, Supplementary Table 2). This sug-
gests that chronic, low, non-toxic dose of DMSO modulates spines
in a region- and genotype-speciﬁc manner, abolishing the differ-
ences in hippocampal spine density between APPSDL and wild-type
mice ex vivo.
Previous studies reported that DMSO suppresses NMDA-
induced ion currents and Ca2þ inﬂux (Lu and Mattson, 2001)
therefore we tested the effect of MK-801, a non-competitive NMDA
receptor antagonist on hippocampal spine density of wild-type and
APPSDL mice (Fig. 1E, Supplementary Table 2). Treatment of slice
cultures with 50 mM MK-801 during 4 days recapitulated the
decrease of spine density in CA1 and CA3 regions of wild-type mice
and the increase in spine density in the CA1 region of APPSDL mice,
closely mimicking the effect of DMSO. MK-801 together with DMSO
did not result in further changes. This ﬁnding suggests that DMSO
modulates spine density via its action on NMDA receptors.
3.2. DMSO treatment modulates hippocampal spine density in a
genotype-speciﬁc manner in vivo
We next aimed to evaluate whether systemic administration of
chronic, low, non-toxic DMSO also inﬂuences hippocampal spine
density in old (17e18M) wild-type and APPSDL male mice in vivo. At
this age, analysis of hippocampal and neocortical regions from
APPSDL brain did not reveal the presence of Ab plaques (data not
shown), conﬁrming thismouse line as a presymptomatic ADmodel.
The distinct mossy ﬁber terminal layer is one of the main
anatomical references to identify the CA2 hippocampal subﬁeld.
Due to the visibility of the entire mossy ﬁber tract in the GFP M
mouse line (Feng et al., 2000) we could include also the analysis of
the CA2 hippocampal pyramidal cells. To rule out a potential toxic
effect of chronic DMSO, water intake as well as body and organ
weights were measured. Body weight of untreated and treated
mice from both genotypes remained stable during the 14 days of
treatment (Supplemental Fig. S1A). Except for the signiﬁcant dif-
ference occurring between untreated and treated wild-typemice in
the weight of the right kidney, no further changes were observed in
organ weight. Daily water intake of mice from both genotypes was
not inﬂuenced by DMSO treatment (Supplemental Figs. S1B and C).
These data strongly suggest that chronic treatment with 1% DMSO
induces neither toxic nor diuretic effects in old mice.
The same DMSO treatment was provided to old (17e18 M) EGFP
and EGFP/APPSDL male mice (Fig. 2A). Dendritic segments from CA1,CA2 and CA3 pyramidal neurons were imaged in the dorsal hip-
pocampus (Supplemental Fig. S2, Fig. 2B). In the absence of DMSO,
spine density was decreased on dendrites of CA1 and CA2 neurons
from EGFP/APPSDL mice compared to control EGFP mice (Fig. 2C,
Supplementary Table 3). DMSO treatment did not alter spine den-
sity on CA1 neurons but increased spine density on dendrites of
CA2 and CA3 neurons of EGFP/APPSDL mice (Fig. 2C, Supplementary
Table 3). Therefore paralleling our previous observations from
ex vivo cultures, in vivo DMSO treatment results in a region- and
genotype-speciﬁc spine change that tends to abolish Ab-mediated
decrease in spine density. However, the effects of DMSO differ be-
tween the two systems. One aspect is that DMSO reduces spine
L. Penazzi et al. / Neuropharmacology 113 (2017) 434e444438density on dendrites of control mice ex vivo, whereas in the in vivo
experiment, this does not seem to happen. The difference may be
caused by the progressive age-related changes of the plastic
properties of neurons or the respective treatment conditions.
3.3. DMSO treatment tends to improve spatial memory accuracy
Potential consequences of chronic DMSO treatment on
hippocampal-dependent spatial memory were tested in old
(17e18 M) wild-type and APPSDL mice using the Barnes maze task
(Barnes, 1979). Untreated adult (7e8 M) mice from both genotypes
were included as additional reference groups for the evaluation of
the performance of old mice. Adult and old mice of both genotypes
successfully learned to locate the target hole, as demonstrated by
the gradual decrease in spatial errors (Fig. 3A, Supplementary
Table 4) and escape latency (Fig. 3B, Supplementary Table 4). A
probe test was conducted one day after the last acquisition day. All
mice retrieved the target location, as indicated by their selective
preference for the target hole compared to chance level (Fig. 3C,
Supplementary Table 4). Adult wild-type and APPSDL mice accu-
rately remembered this position as they visited signiﬁcantly more
the target hole than the immediately adjacent holes. In contrast, old
untreated wild-type and APPSDL mice displayed a broader search
pattern that extended to the immediately adjacent holes, indicating
a non-speciﬁc effect of aging on spatial memory accuracy.Fig. 3. Chronic DMSO treatment modulates spatial memory accuracy and retrieval ind
showed signiﬁcant decrease in number of spatial errors before the ﬁrst target exit hole visit
Wild-type mice: þ P < 0.05, þþ P < 0.01 and þþþ P < 0.001, versus day 1; APPSDL mice: $ P <
presented a speciﬁc visit of the target hole. Old, untreated wild-type and APPSDL mice sho
speciﬁcally improved the memory accuracy performance of old APPSDL mice compared to the
the red line. All values are represented as mean ± S.E.M. *P < 0.05, **P < 0.01 and ***P < 0.00
(AeC) Adult untreated: wild-type (n ¼ 6) and APPSDL mice (n ¼ 7). Old treated and untreate
by post-hoc Newman-Keuls multiple comparison test. (C) For chance level, Student's t-testInterestingly, drug effect in old mice was close to reach signiﬁcance
(P¼ 0.08, see Supplementary Table 4). Detailed analyses conﬁrmed
that DMSO treated APPSDL mice signiﬁcantly focused their search
on the target hole whereas vehicle treated APPSDL mice evenly
explored target and neighboring holes. This suggests that DMSO
treatment tends to increase spatial memory accuracy in APPSDL
mice.
We further examined whether DMSO treatment modulates
brain activation during spatial memory retrieval using the neuronal
activity marker c-fos (Bullitt, 1990). Semi-automatic detection and
quantiﬁcation of c-fos-positive cell nuclei (Penazzi et al., 2014)
(Supplemental Fig. S3) was performed in the DG, CA3 and CA1
regions of the dorsal hippocampus and in the lateral parietal (LPar)
and retrosplenial granular (RSGc) cortices of untreated and treated
old wild-type and APPSDL mice, both in basal home cage condition
and after spatial memory retrieval. Under basal condition, APPSDL
mice displayed hyperactivated DG and CA1 neurons and reduced
neuronal activation in the CA3 region (Fig. 4A, Supplementary
Table 5). DMSO treatment normalized this Ab-mediated alteration
of basal neuronal activation in CA1 and DG to the level of wild-type
mice. In the neocortex, no differences were observed in basal
neuronal activation in the regions analyzed. However, DMSO
increased neuronal activation in the RSGc of wild-type mice (Fig. 4
B, Supplementary Table 5). Taken together, DMSO showed a region-
and genotype-speciﬁc inhibitory effect on neuronal activationuced neuronal activation. (AeC) Barnes maze test. (A) Across training sessions, mice
and (B) reduced escape latency. (A,B) Data are expressed as daily average of three trials.
0.05, $$ P < 0.01 and $$$ P < 0.001, versus day 1. (C) During the probe trial, adult mice
wed a signiﬁcantly decreased precision in their search pattern and DMSO treatment
ir untreated counterparts. Opposite (O) and target (T) holes. Chance level is indicated by
1, versus target exit hole. £ P < 0.05, ££ P < 0.01 and £££ P < 0.001, versus chance level.
d: wild-type and APPSDL mice (n ¼ 7 mice/group). Repeated measures ANOVA followed
. For detailed statistics see Supplementary Table 4.
Fig. 4. Chronic DMSO treatment modulates neuron activation in a genotype- and region-speciﬁc manner. (A) DMSO treatment affects the expression of c-Fos under basal home
cage condition in a genotype-speciﬁc manner in the DG, CA3, CA1 of the dorsal hippocampus and LPar. Insert at right panel shows rescaled graph of the same. (B) DMSO treatment
also affects c-fos positive cell nuclei in the retrosplenial granular cortex (RSGc) under basal home cage condition (A,B left) n ¼ 4e5 mice/group. (B, right) n ¼ 6e7 mice/group.
*P < 0.05, **P < 0.01 and ***P < 0.001, wild-type versus APPSDL mice, same experimental condition. #P < 0.05, ##P < 0.01 and ###P < 0.001, signiﬁcantly decreased compared to
untreated same genotype. (C) DMSO treatment modulates spatial memory retrieval-related c-fos positive cell density in a region and genotype-speciﬁc manner by decreasing c-fos
density in the CA3 region of APPSDL mice, by increasing c-fos density in the CA1 region of wild-type mice and by inducing a signiﬁcant difference between both genotypes in the LPar
region. No signiﬁcant effect occurred in the DG. Old treated and untreated wild-type and APPSDL mice (n ¼ 6e7 mice/group). All values are represented as mean ± S.E.M. *P < 0.05
and **P < 0.01, wild-type versus APPSDL, same experimental condition. #P < 0.05, signiﬁcantly decreased and þ P < 0.05 signiﬁcantly increased compared to untreated, same
genotype. Factorial ANOVA followed by post-hoc Fisher's LSD for multiple comparisons. For detailed statistics see Supplementary Table 5.
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campus of APPSDL mice.
The spatial memory retrieval resulted in comparable neuronal
activation between wild-type and APPSDL mice in all hippocampal
and neocortical regions analyzed (Fig. 4B and C, SupplementaryTable 5) suggesting that Ab-mediated alteration of neuronal acti-
vation was speciﬁc to baseline condition. DMSO treatment signiﬁ-
cantly reduced neuronal activation in the CA3 region of APPSDL mice
but raised the level of neuronal activity in the CA1 region of wild-
type mice compared to untreated mice from the same genotype
L. Penazzi et al. / Neuropharmacology 113 (2017) 434e444440(Fig. 4C, Supplementary Table 5). In the LPar, DMSO induced a
signiﬁcant difference in c-Fos expression between wild-type and
APPSDL mice that was not apparent in untreated condition. No
changes were induced by DMSO in the RSGc of mice from both
genotypes (Fig. 4B, Supplementary Table 5). Therefore, chronic
DMSO treatment modulates both basal and spatial memory
retrieval induced neuronal activation in a region- and genotype-
speciﬁc manner.
3.4. DMSO treatment restores olfactory sensitivity
Inﬂuence of chronic DMSO treatment on olfactory behavior was
determined in old (17e18 M) wild-type and APPSDL male mice
utilizing an odor habituation task (Fig. 5A). Again, untreated adult
(7e8 M) mice served as an additional control for the evaluation of
the performance of old mice. No difference was observed in nose
poke (NP) duration between the two genotypes of adult mice.
However, all along the odor sampling period, NP duration of old
APPSDL mice was signiﬁcantly higher (Fig. 5B, Supplementary
Table 6), a difference abolished by DMSO treatment, which
normalized NP duration to the level of age-matchedwild-typemice
and adult mice of the same genotype. In contrast, NP number was
only increased in old wild-type mice, which did not differ any
longer from the level of adult mice after DMSO treatment (Fig. 5C,
Supplementary Table 6). We examined the investigation time
during the ﬁrst ﬁve NPs, as an indicator of odor habituation. Only
old, untreated APPSDL mice displayed a delayed habituation, high-
lighted by the absence of a gradual decrease between the ﬁrst and
fourth NP duration. Interestingly, for the ﬁrst three NPs, the olfac-
tory performance of old APPSDL mice was normalized to the level of
old wild-type mice by chronic DMSO (Fig. 5D, Supplementary
Table 7), indicating that Ab-induced decreased olfactory habitua-
tion was attenuated by DMSO treatment.
3.5. DMSO treatment attenuates anxiety-related behavior
DMSO has been previously reported to display anxiolytic
properties (Matheus et al., 1997). Whether chronic DMSO treat-
ment modulates anxiety-like behavior in old wild-type and APPSDL
male mice was determined using the elevated-plus maze test. As
before, untreated adult (7e8 M) mice served as reference control
for the evaluation of the performance of old mice. Adult APPSDL
mouse behavior was indistinguishable from wild-type mice in
terms of distance travelled (Fig. 6A, Supplementary Table 8),
number of entries (Fig. 6B, Supplementary Table 8), percentage of
entries in open arms (Fig. 6C, Supplementary Table 8) and per-
centage of time spent in open arms (Fig. 6D, Supplementary
Table 8). In contrast, old APPSDL mice signiﬁcantly differed from
old wild-type mice with respect to the distance travelled, the
number of entries and the percentage of time spent in open arms,
indicating a genotype-speciﬁc effect of aging on anxiety-like
behavior. DMSO treatment induced a signiﬁcant decrease of the
number of entries for old wild-type mice and abolished the dif-
ferences in the percentage of entries and time spent in open arms
for APPSDL mice, which furthermore did not differ from chance level
anymore. In contrast, time spent in open arms by old treated wild-
type mice was signiﬁcantly lower than chance level after DMSO
treatment. These data suggest that the age-related increase of
anxiety-like behavior in old APPSDL animals is attenuated by
chronic DMSO treatment. On the opposite, DMSO treatment may
display anxiogenic effects in old wild-type animals.
4. Discussion
DMSO has already been tested in several clinical trials morethan 3 decades ago (Swanson, 1985), and some of its biological
activities have shown to be beneﬁcial against various pathologies,
such as dermatologic, urinary, pain or inﬂammatory disorders
(Santos et al., 2003; Yu and Quinn,1994). Nevertheless the effect on
the CNS structure and function had been remarkably ignored. In the
present study, we demonstrate for the ﬁrst time that chronic
treatment with low, non-toxic DMSO dose displays region- and
genotype-speciﬁc modulating actions on (i) hippocampal spine
density, both ex vivo and in vivo, (ii) hippocampal-dependent and
independent behavior, and (iii) neuronal activity, abolishing the
differences observed between old APPSDL and wild-type male mice.
After intravenous and cutaneous application, DMSO shows a fast
(within few hours) and approximately equal distribution in soft
tissues, including brain. There is no evidence for accumulation of
DMSO in the brain tissue and the elimination occurs within
12e36 h in experimental animals (Denko et al., 1967; Kolb et al.,
1967). However at high doses, DMSO presents diuretic properties
(Suominen and Uusi-Penttila, 1968), resulting in altered water
consumption. Here, we have shown that chronic treatment with 1%
DMSO neither modiﬁed daily water intake nor resulted in a dra-
matic change in organ weight, suggesting that 14 days of chronic
treatment with 1% DMSO is generally not harmful for old mice. Low
concentrations of DMSO have been shown to induce neurochemical
(Matsumoto et al., 1985; Nasrallah et al., 2008; Obregon et al., 2005)
and neuroelectrical changes (Lu and Mattson, 2001; Nakahiro et al.,
1992; Tamagnini et al., 2014; Tsvyetlynska et al., 2005), which
consequently might result in plastic synaptic changes. Yet, to date
structural changes in synaptic connectivity and their potential ef-
fect on behavior after systemic, chronic administration of DMSO
were barely investigated.
Under physiological conditions, naturally secreted Ab peptides
are known to regulate CNS function (Cirrito et al., 2005). However,
increased concentrations of soluble Ab (Wei et al., 2010) cause a
marked decrease in spine density, which has been shown to be
reversible (Smith et al., 2009). In our transgenic APPSDL mouse
model, Ab resulted in a region-speciﬁc decrease of spine density on
hippocampal neurons, in both organotypic slice cultures and in the
brain, which was region-speciﬁcally counteracted by DMSO treat-
ment. The intrinsic properties of neurons from these hippocampal
subﬁelds have been reported to differ in many aspects, including
their NMDA and AMPA receptor content (Martens andWree, 2001),
determining their sensitivity to Ca2þ (Grishin et al., 2004). Low
DMSO dose has been shown to decrease Ca2þ responses to gluta-
mate, protecting hippocampal neurons from excitotoxic death (Lu
and Mattson, 2001). We and others have shown that Ab-induced
spine pathology involves NMDA receptor activation (Tackenberg
and Brandt, 2009). Obtaining memory facilitating effects from an
NMDA receptor antagonist may sound counterintuitive. However,
improvement of memory performances by a NMDA receptor
antagonist had been repeatedly shown in a wide range of disease
models associated with memory disturbances (Marszalek-Grabska
et al., 2016; Scholtzova et al., 2008) but also in non-diseased ani-
mals depending on the type of task, timing and dose provided
(Mondadori and Weiskrantz, 1993; Puma and Bizot, 1998). Here we
provide evidence suggesting that spine density modulation by
DMSO is indeed achieved by its action on NMDA receptors, since an
NMDAR antagonist, MK-801 recapitulated the effect of DMSO on
spine density in organotypic slice cultures.
Modulation of cell signaling by low concentrations of DMSO
could also explain the differential regulation of neuronal activation
in various brain regions, as determined by the c-Fos expression
analysis. The most obvious examples include the subregions that
elicit Ab-related hyperactivity. These data are consistent with
recent work reporting that changes in neuronal activation occur
independently of plaque deposition due to the presence of soluble
Fig. 5. Chronic DMSO treatment restores olfactory habituation of old transgenic mice. (A) Time line of the experiment. (B) Mean of nose poke (NP) duration does not vary
between adult mice of both genotypes. NP duration of untreated APPSDL mice signiﬁcantly increased with aging compared to adult mice of the same genotype but is reduced by
DMSO treatment. (C) Mean number of nose pokes is signiﬁcantly increased for old untreated wild-type mice compared to adult mice of the same genotype, a difference abolished by
DMSO treatment. (D) Progressive decrease in the duration of the ﬁrst ﬁve nose pokes occurs for adult mice, indicating habituation to new odorants. Odor habituation of old
untreated APPSDL mice signiﬁcantly differs from the performance of adult mice from the same genotype, and from old untreated wild-type mice, whereas DMSO treatment
signiﬁcantly attenuates olfactory deﬁcits of APPSDL mice. Adult wild-type (n ¼ 6) and APPSDL mice (n ¼ 7), old wild-type and APPSDL mice (n ¼ 6e7 mice/group). All values are
represented as mean ± S.E.M. (B) *P < 0.05, **P < 0.01, wild-type versus APPSDL, same experimental condition. ##P < 0.01 signiﬁcantly decreased compared to untreated, same
genotype. (D) *P < 0.05, **P < 0.01 and ***P < 0.001, versus ﬁrst nose poke. (BeD) ¤ P < 0.05, ¤¤ P < 0.01 and ¤¤¤ P < 0.001, versus adult animal of the same genotype. (B,C) Adult
mice, one way ANOVA and old untreated and treated mice, factorial ANOVA. (D) Repeated measures ANOVA. (F) Factorial ANOVA. (B,C and F) post hoc Fisher's LSD for multiple
comparisons. (D) post hoc Tukey's test. For detailed statistics see Supplementary Tables 6 and 7.
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tion has also been reported in cognitively impaired individuals at
high risk to convert to AD (Dickerson et al., 2005). Interestingly,
pharmacological reduction of hippocampal hyperactivation in such
individuals improved their memory performances (Bakker et al.,
2012). Here we showed that DMSO exerts a beneﬁcial inﬂuence
through the normalization of this pathological trait. It shouldhowever be noticed that DMSO is a very interesting molecule: it
contains a hydrophilic and a hydrophobic part, and in the same
time it is a dipole molecule with polar character. Already early
studies described DMSO being effective in reversibly altering the
conﬁguration of proteins (Rammler and Zaffaroni, 1967). Later on in
silicomolecular dynamics analysis as well as cell studies pointed to
a concentration dependent membrane altering effect of DMSO (de
Fig. 6. Chronic DMSO treatment is anxiolytic for old APPSDL mice but anxiogenic
for old wild-type animals. (AeD) Adult mice of both genotypes did not show a sig-
niﬁcant difference in any parameter measured during elevated-plus maze. (A) A sig-
niﬁcant difference, which was abolished by DMSO treatment, was apparent between
old treated and untreated wild-type and APPSDL mice regarding the distance travelled,
(B) the number of entries and (D) the time spent in open arms. (C) No signiﬁcant
difference was evident in percentage of entries into the open arms between the two
genotypes. (C,D) Chance level is indicated by the red line. (AeD) Adult wild-type
(n ¼ 6) and APPSDL mice (n ¼ 7), old wild-type and APPSDL mice (n ¼ 7 mice/group).
All values are represented as mean ± S.E.M. (AeD) *P < 0.05, **P < 0.01 and
***P < 0.001, wild-type versus APPSDL mice, same experimental condition. (B) #P < 0.05
signiﬁcantly decreased compared to untreated, same genotype. (C,D) £ P < 0.05 and £££
P < 0.001 versus chance level (50%). (AeD) Adult mice, one-way ANOVA; old untreated
and treated mice, factorial ANOVA. (CeD) Student 's t-test for chance level. (AeD) post
hoc Fisher's LSD test for multiple comparisons. For detailed statistics see
Supplementary Table 8.
Fig. 7. Chronic DMSO treatment does not change the oligomeric Ab level. Student's
t-test conﬁrmed that the levels of soluble and membrane bound Ab oligomers were
not changed between untreated and DMSO treated APPSDL mouse brain tissue of the
(A) the hippocampus and (B) olfactory bulb. All values are represented as
mean ± S.E.M. For detailed statistics see Supplementary Table 9.
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therefore pleiotropic actions, implying that part of the beneﬁcial
effects might also be attributed to a more global inﬂuence of this
compound. Previously, high DMSO concentrations have been pro-
posed to alter Ab aggregation (Shen and Murphy, 1995). However,
our investigation of the oligomeric Ab (oAb) amount in both, OB
and hippocampus of APPSDL mice showed no difference due to
DMSO used at low dose (Fig. 7, Supplementary Table 9), indicating
that the beneﬁcial effect of DMSO is not caused by decreased levels
of oAb and conﬁrming that the mode of action of DMSO is highly
concentration dependant.
DMSO-mediated changes on spines are likely to affect synaptic
plasticity underlying hippocampal-dependent learning and mem-
ory. Indeed, age-related decrease in spatial memory accuracy was
attenuated with 1% DMSO treatment for APPSDL mice. However,
DMSO might modulate also hippocampal-independent behavior.
Altered olfactory function has been associated with amyloidosis-
related pathologies and might represent an informative
biomarker to diagnose the earliest stage of neuropathologies, such
as AD or PD (Alvarado-Martinez et al., 2013; Jimbo et al., 2011;
Wesson et al., 2010). This has been further conﬁrmed by a very
recent study in humans, where it has been suggested that olfactory
tests have the potential for screening for MCI and MCI that is likely
to progress to AD (Roberts et al., 2015). Here, we found that oldAPPSDL mice displayed decreased olfactory habituation compared
to wild-type mice. Interestingly, chronic DMSO normalized APPSDL
olfactory performances to the level of adult mice. Differences in
anxiety-like behaviors between APPSDL andwild-typemice develop
with aging. Consistent with previous work (Matheus et al., 1997),
DMSO treatment displayed a moderate anxiolytic effect in old
APPSDL mice. Intriguingly, chronic DMSO appeared to be anxiogenic
for old wild-type mice by mildly decreasing the time spent in open
arms.
4.1. Conclusions
Currently, DMSO continues to be one of the most used vehicle in
the evaluation of potential hydrophobic drug candidates in basic
biological research. Our data highlight unexpected effects of sys-
temic administration of chronic, low, non-toxic DMSO with a dif-
ferential effect in wild-type and APPSDL mice. Thus, DMSO should
be considered as a true bioactive compound whose mechanisms of
action might be beneﬁcial against some neurodegenerative condi-
tions. Consequently, the effects of chronic DMSO on synaptic
plasticity and behavior are important to be considered for the
development of appropriate therapies for neurodegenerative
diseases.
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